There are currently 44 active clinical trials seeking participants for Systemic Lupus Erythematosus research studies. The states with the highest number of trials for Systemic Lupus Erythematosus participants are California, Florida, Texas and New York.
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
NCT05001737
Recruiting
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.
Gender:
All
Ages:
Between 6 months and 80 years
Trial Updated:
04/16/2024
Locations: UAB Hospital, Birmingham, Alabama +48 locations
Conditions: Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
Register for Updates
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
NCT01931644
Recruiting
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/15/2024
Locations: Sanguine Biosciences, Los Angeles, California
Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Register for Updates
A Study of Imvotamab in Severe Systemic Lupus Erythematosus
NCT06041568
Recruiting
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have failed prior therapies. Participants will be given imvotamab through a vein (i.e., intravenously).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: TriWest Research Associates, San Diego, California +9 locations
Conditions: Systemic Lupus Erythematosus, Lupus Erythematosus
Register for Updates
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
NCT00198068
Recruiting
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications... Read More
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
04/05/2024
Locations: Northwestern University, Chicago, Illinois +9 locations
Conditions: Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Register for Updates
A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
NCT05638802
Recruiting
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Pinnacle Research Group LLC, Anniston, Alabama +11 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
FT819 in Moderate to Severe Active Systemic Lupus Erythematosus
NCT06308978
Recruiting
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following conditioning chemotherapy in participants with moderate to severe active systemic lupus erythematosus (SLE). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: University of Minnesota Medical School, Minneapolis, Minnesota +1 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)
NCT02633163
Recruiting
The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care respond better than patients receiving placebo infusion plus standard of care.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/29/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +8 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
NCT00775476
Recruiting
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the depletion of glutathione in lymphocytes of patients with SLE and associated this metabolic change with the elevation of the mitochondrial transmembrane potential. This study will titrate to tolerance during an initial 3 mo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +4 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327
Recruiting
The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569_0003 [NCT05162586]).
Gender:
All
Ages:
Between 18 years and 76 years
Trial Updated:
02/19/2024
Locations: Advance Medical Research Center, Miami, Florida +66 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Safety of the Herpes Zoster Subunit Vaccine in Lupus
NCT05559671
Recruiting
This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
02/16/2024
Locations: NYU Langone Health, New York, New York +1 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Centrally Acting ACE Inhibition in SLE
NCT04486118
Recruiting
SLE is a chronic autoimmune disease that often involves multiple systems and organs of the body. An autoimmune disease is one which your immune system attacks the cells and tissues in different parts of the body. SLE is characterized by inflammation that leads to tissue damage in many different organ systems. Lupus can cause fever, joint pains, rashes, and other symptoms. It can also affect organs such as the skin, the muscles, the kidneys, the heart, the lungs, the blood and the brain. The exac... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/09/2024
Locations: Yale University School of Medicine, New Haven, Connecticut +6 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
NCT03276923
Recruiting
This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases. The main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy. Prior studies demonstrate the importance of increase inflammation prior to and during pregnancy on these outcomes. The future research will seek to better define these risk factors and to identify ways to may improve them.
Gender:
Female
Ages:
All
Trial Updated:
01/25/2024
Locations: Duke University, Durham, North Carolina
Conditions: Autoimmune Diseases, Pregnancy Related, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Register for Updates